

CA-4948-203: A Ph2 Study of Emavusertib + an Approved BTKi in Patients with CLL and Other B-cell Malignancies

Estado

Reclutando

Tipo de Participantes

No aportado

Rangos de Edad

Mayores de 64 , Adultos (18-64 años)

Género

Ambos

Fases

Fase II

Participantes esperados

80

Resultados

Sin resultados

Bajo nivel intervención

No

Enfermedad rara

No

Cobertura geográfica

Sin determinar

Ámbitos del ensayo

seguridad, eficacia, farmacocinética,
farmacodinámica, farmacogenética

Terapia avanzada

NO

Información

Identificador

2025-523600-68-00 (CTIS)

Cod. Protocolo

CA-4948-203

Área terapéutica

Enfermedades [C] - Cáncer [C04]

Enfermedad investigada

Chronic Lymphocytic Leukemia and Other B-cell Malignancies

Título Científico

A Phase 2 Study of Emavusertib in Combination with an Approved Bruton Tyrosine Kinase Inhibitor in Patients with Chronic Lymphocytic Leukemia and Other B-cell Malignancies

Justificación

No aportado

Objetivo Principal

Cohort 1 and Cohort 2:

Assess the anticancer activity of emavusertib in combination with zanubrutinib

Variables de Evaluación Primaria

1.Cohort 1: undetectable measurable residual disease (uMRD) rate: percentage of patients achieving uMRD as measured in peripheral blood mononuclear cells (PBMCs) by the ClonoSEQ assay. Bone marrow aspirate is required to confirm a CR and uMRD by peripheral blood.

2.Cohort 2: ORR: percentage of patients achieving a complete response (CR), or PR using iwCLL Response Criteria guidelines (Hallek et al, 2018)

Momentos temporales de evaluación primaria

No aportado

Objetivo Secundario

Cohort 1 and Cohort 2: Further assess anticancer activity of emavusertib in combination with zanubrutinib Evaluate the safety and tolerability of emavusertib in combination with zanubrutinib Assess the exposure profile of emavusertib in combination with zanubrutinib

Variables de Evaluación Secundaria

1.Cohort 1: Duration of uMRD, Time to measurable residual disease (MRD) conversion, complete response (CR) rate, Duration of CR, Time to CR

2.Cohort 2: Duration of response (DOR), Time to response

3.Cohort 1 and Cohort 2: Progression-free survival (PFS), Overall survival (OS) Incidence of treatment-emergent adverse events (TEAEs) and treatment-related AEs, physical examinations, vital signs, electrocardiograms (ECGs), and laboratory values PK parameters: Cmax, Tmax, AUC0-t, and Cmin for emavusertib and zanubrutinib

Momentos temporales de evaluación secundaria

No aportado

Criterios de Inclusión

1. Age 18 years of age with life expectancy of 3 months. 10. For Cohort 1 only: Patient must be in a PR or PR-L and MRD+, must have detectable MRD as determined by the ClonoSEQ assay, actively taking zanubrutinib for at least 12 months, acceptable organ function (protocol-defined) at Screening within 28 days prior to Cycle 1 Day 1 (C1D1) 11. For Cohort 2 only: Relapsed disease (protocol-defined) for which patients are ineligible for or exhausted standard of care options; Actively taking zanubrutinib and with direct progression on zanubrutinib and no other anticancer therapy administered since; Acceptable organ function (protocol-defined) at Screening within 28 days prior to C1D1. 2. Eastern Cooperative Oncology Group Performance Status of 2; 3. Histopathologically confirmed diagnosis of CLL per the World Health Organization 2016 classification; 4. At least 1 criterion for measurable disease per iwCLL; creatine phosphokinase (CPK) < 2.5 × upper limit of normal (ULN); 5. Ability to tolerate contrast-enhanced computed tomography (CT) scan; 6. Ability to swallow/retain oral medications; 7. Negative serum pregnancy test in women of childbearing potential (WOCP); 8. WOCP and men who partner with WOCP must use highly effective contraceptive methods during study and 180 days after the last dose of study treatment; 9. Ability to understand/sign a written informed consent document.

Criterios de Exclusión

1. Active second malignancy unless in remission with life expectancy > 2 years; 10. History of Stevens-Johnson syndrome or toxic epidermal necrolysis; 11. Intolerance to contrast-enhanced CT scan: Major surgery < 28 days prior to C1D1, minor surgery < 7 days prior to C1D1. Viral infections (protocol-defined); 12. Concomitant illness that would preclude safe participation in the study. 2. Active malignancy other than CLL requiring systemic therapy; 3. high-risk CLL TP53 mutations and 17P deletion; 4. History of Grade 3 rhabdomyolysis without complete recovery; 5. Prior chimeric antigen receptor-T cell therapy; 6. Prior investigational drugs within 28 days or 5 half-lives, whichever is shorter, prior to C1D1: allogeneic hematopoietic stem cell transplant (HSCT) within 60 days prior to C1D1, or clinically significant graft-versus-host disease (GVHD) requiring ongoing up titration of immunosuppressive medications prior to Screening; Prior systemic anticancer treatment received within 21 days or 5 half-lives, whichever is shorter, prior to C1D1 (with the exception of zanubrutinib, which may be continued until the day before C1D1); 7. Receiving the following medications within 7 days or 5 half-lives, whichever is shorter, prior to C1D1: Medications that have a high risk of causing prolonged QT interval, corrected (QTc) and/or Torsades de Pointes, Peg-filgrastim or equivalent, St Johns Wort; 8. History of or ongoing drug-induced pneumonitis, History of stroke or intracranial hemorrhage within 6 months prior to C1D1, Requirement for anticoagulation with warfarin or equivalent vitamin K antagonists, including dual antiplatelet agents, within 5 half-lives of the anticoagulant or 7 days, whichever is longer, prior to C1D1; 9. Vaccinated with a live-attenuated vaccine within 4 weeks prior to C1D1: History of hypersensitivity or anaphylaxis to ema, approved BTKi, or any of their excipients;

Calendario

(Última actualización: 25/08/2026)

Autorización 16/03/2026	Inicio de Ensayo 19/05/2026	Inclusión Primer Paciente No aportado	Interrumpido No aportado	Reiniciado No aportado
Fin de reclutamiento No aportado	Fin prematuro (España) No aportado	Fin prematuro (Global) No aportado	Fin del ensayo en España No aportado	Fin del ensayo global No aportado

Promotor

Curis Inc. United States
128 Spring Street Suite 500 Building C

Contact Person
Medical Affairs
+16175036500
clinicaltrials@curis.com

Monetary support: N/A
Tipo de promotor: Comercial

Ceim

CEIm Hospital Clínico San Carlos

C/ Doctor Martín Lagos, s/n - Ciudad Universitaria 28040 Madrid

ceic.hcsc@salud.madrid.org

917044160

Centros

Hospital Universitario Fundacion
Jimenez Diaz

Madrid

MADRID

Hematology

Activo (19/05/2026)

MD Anderson Cancer Center

Madrid

MADRID

Hematology

Activo (29/05/2026)

Medicamentos

CA-4948

COATED TABLET

ORAL USE

—

Principios Activos: N/A

Experimental

CA-4948

COATED TABLET

ORAL USE

—

Principios Activos: N/A

Experimental

BRUKINSA 80 mg hard capsules

CAPSULE, HARD

ORAL USE

Código ATC: L01EL03 - ZANUBRUTINIB

Principios Activos: N/A

Experimental

BRUKINSA 160 mg film-coated tablets

FILM-COATED TABLET

ORAL USE

Código ATC: L01EL03 - ZANUBRUTINIB

Principios Activos: N/A

Experimental

BRUKINSA 160 mg film-coated tablets

FILM COATED TABLET

ORAL USE

Código ATC: L01EL03 - ZANUBRUTINIB

Principios Activos: N/A

Experimental

Sin resultados

CA-4948-203: A Ph2 Study of Emavusertib + an Approved BTKi in Patients with CLL and Other B-cell Malignancies

State
Recruiting

Type of participants
Not provided

Age Ranges
Older than 64 , Adults (18-64 years)

Gender
Both

Phases
Phase II

Expected Participants
80

Results
No results

Low level of intervention
No

Rare disease
No

Geographic coverage
Undetermined

Areas of the study
safety, effectiveness, pharmacokinetics,
pharmacodynamics, pharmacogenetics

Advanced therapy
NO

Information

Identifier
2025-523600-68-00 (CTIS)

Protocol Code
CA-4948-203

Therapeutic area
Diseases [C] - Cancer [C04]

Investigated Disease
Chronic Lymphocytic Leukemia and Other B-cell Malignancies

Scientific Title
A Phase 2 Study of Emavusertib in Combination with an Approved Bruton Tyrosine Kinase Inhibitor in Patients with Chronic Lymphocytic Leukemia and Other B-cell Malignancies

Rationale

Not provided

Main Objective

Cohort 1 and Cohort 2:

Assess the anticancer activity of emavusertib in combination with zanubrutinib

Primary Endpoints

1.Cohort 1: undetectable measurable residual disease (uMRD) rate: percentage of patients achieving uMRD as measured in peripheral blood mononuclear cells (PBMCs) by the ClonoSEQ assay. Bone marrow aspirate is required to confirm a CR and uMRD by peripheral blood.

2.Cohort 2: ORR: percentage of patients achieving a complete response (CR), or PR using iwCLL Response Criteria guidelines (Hallek et al, 2018)

Temporary moments of secondary assessment

Not provided

Secondary Objective

Cohort 1 and Cohort 2: Further assess anticancer activity of emavusertib in combination with zanubrutinib Evaluate the safety and tolerability of emavusertib in combination with zanubrutinib Assess the exposure profile of emavusertib in combination with zanubrutinib

Secondary Endpoints

1.Cohort 1: Duration of uMRD, Time to measurable residual disease (MRD) conversion, complete response (CR) rate, Duration of CR, Time to CR

2.Cohort 2: Duration of response (DOR), Time to response

3.Cohort 1 and Cohort 2: Progression-free survival (PFS), Overall survival (OS) Incidence of treatment-emergent adverse events (TEAEs) and treatment-related AEs, physical examinations, vital signs, electrocardiograms (ECGs), and laboratory values PK parameters: Cmax, Tmax, AUC0-t, and Cmin for emavusertib and zanubrutinib

Temporary moments of secondary assessment

Not provided

Inclusion criteria

1. Age 18 years of age with life expectancy of 3 months. 10. For Cohort 1 only: Patient must be in a PR or PR-L and MRD+, must have detectable MRD as determined by the ClonoSEQ assay, actively taking zanubrutinib for at least 12 months, acceptable organ function (protocol-defined) at Screening within 28 days prior to Cycle 1 Day 1 (C1D1) 11. For Cohort 2 only: Relapsed disease (protocol-defined) for which patients are ineligible for or exhausted standard of care options; Actively taking zanubrutinib and with direct progression on zanubrutinib and no other anticancer therapy administered since; Acceptable organ function (protocol-defined) at Screening within 28 days prior to C1D1. 2. Eastern Cooperative Oncology Group Performance Status of 2; 3. Histopathologically confirmed diagnosis of CLL per the World Health Organization 2016 classification; 4. At least 1 criterion for measurable disease per iwCLL; creatine phosphokinase (CPK) < 2.5 × upper limit of normal (ULN); 5. Ability to tolerate contrast-enhanced computed tomography (CT) scan; 6. Ability to swallow/retain oral medications; 7. Negative serum pregnancy test in women of childbearing potential (WOCP); 8. WOCP and men who partner with WOCP must use highly effective contraceptive methods during study and 180 days after the last dose of study treatment; 9. Ability to understand/sign a written informed consent document.

Exclusion criteria

1. Active second malignancy unless in remission with life expectancy > 2 years; 10. History of Stevens-Johnson syndrome or toxic epidermal necrolysis; 11. Intolerance to contrast-enhanced CT scan: Major surgery < 28 days prior to C1D1, minor surgery < 7 days prior to C1D1. Viral infections (protocol-defined); 12. Concomitant illness that would preclude safe participation in the study. 2. Active malignancy other than CLL requiring systemic therapy; 3. high-risk CLL TP53 mutations and 17P deletion; 4. History of Grade 3 rhabdomyolysis without complete recovery; 5. Prior chimeric antigen receptor-T cell therapy; 6. Prior investigational drugs within 28 days or 5 half-lives, whichever is shorter, prior to C1D1: allogeneic hematopoietic stem cell transplant (HSCT) within 60 days prior to C1D1, or clinically significant graft-versus-host disease (GVHD) requiring ongoing up titration of immunosuppressive medications prior to Screening; Prior systemic anticancer treatment received within 21 days or 5 half-lives, whichever is shorter, prior to C1D1 (with the exception of zanubrutinib, which may be continued until the day before C1D1); 7. Receiving the following medications within 7 days or 5 half-lives, whichever is shorter, prior to C1D1: Medications that have a high risk of causing prolonged QT interval, corrected (QTc) and/or Torsades de Pointes, Peg-filgrastim or equivalent, St Johns Wort; 8. History of or ongoing drug-induced pneumonitis, History of stroke or intracranial hemorrhage within 6 months prior to C1D1, Requirement for anticoagulation with warfarin or equivalent vitamin K antagonists, including dual antiplatelet agents, within 5 half-lives of the anticoagulant or 7 days, whichever is longer, prior to C1D1; 9. Vaccinated with a live-attenuated vaccine within 4 weeks prior to C1D1: History of hypersensitivity or anaphylaxis to ema, approved BTKi, or any of their excipients;

Calendar

(Last Update: 25/08/2026)

Authorization 16/03/2026	Start of Trial 19/05/2026	First patient inclusion Not aported	Halted Not aported	Restarted Not aported
End of recruitment Not aported	Premature end (Spain) Not aported	Premature End (Global) Not aported	Trial end (Spain) Not aported	Trial end (Global) Not aported

Sponsor

Curis Inc. United States

128 Spring Street Suite 500 Building C

Contact Person

Medical Affairs

+16175036500

clinicaltrials@curis.com

Monetary support: N/A

Sponsor type: Commercial

Ceim

CEIm Hospital Clínico San Carlos

C/ Doctor Martín Lagos, s/n - Ciudad Universitaria 28040 Madrid

ceic.hcsc@salud.madrid.org

917044160

Sites

Active (19/05/2026)	Hospital Universitario Fundacion Jimenez Diaz	
	Madrid	
	MADRID	Hematology

Active (29/05/2026)	MD Anderson Cancer Center	
	Madrid	
	MADRID	Hematology

Medication

CA-4948

COATED TABLET

ORAL USE

—

Active Principles: N/A

Experimental

CA-4948

COATED TABLET

ORAL USE

—

Active Principles: N/A

Experimental

BRUKINSA 80 mg hard capsules

CAPSULE, HARD

ORAL USE

ATC code: L01EL03 - ZANUBRUTINIB

Active Principles: N/A

Experimental

BRUKINSA 160 mg film-coated tablets

FILM-COATED TABLET

ORAL USE

ATC code: L01EL03 - ZANUBRUTINIB

Active Principles: N/A

Experimental

BRUKINSA 160 mg film-coated tablets

FILM COATED TABLET

ORAL USE

ATC code: L01EL03 - ZANUBRUTINIB

Active Principles: N/A

Experimental

No results